Efficacy and Safety of Rituximab-Based Treatments in Angioedema With Acquired C1-Inhibitor Deficiency
The Journal of Allergy and Clinical Immunology: In Practice · 2024
DOI: 10.1016/j.jaip.2023.10.017 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2024. Verfasst von Galith Kalmi und 26 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Department, Sorbonne Université, AP-HP, Hôpital Saint Antoine, Paris, France. Electronic address: galith.kalmi@aphp.fr. Hauptthemen laut MEDLINE: Angioedema, Angioedemas, Hereditary. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Angioedema (AE) due to acquired C1-inhibitor (C1-INH) deficiency (AAE-C1-INH) is related to excessive consumption of C1-INH or to anti-C1-INH antibodies, and is frequently associated with lymphoproliferative syndromes or monoclonal gammopathies. Standard of care for prophylactic treatment in this condition is not established. Rituximab may be effective to prevent attacks, especially if the lymphoid hemopathy is controlled, but data are scarce. OBJECTIVE: To evaluate efficacy of rituximab in AAE-C1-INH. METHODS: A retrospective multicenter study was carried out in France, including patients with AAE-C1-INH treated with rituximab between April 2005 and July 2019. RESULTS: Fifty-five patients with AAE-C1-INH were included in the study, and 23 of them had an anti-C1-INH antibody. A lymphoid malignancy was identified in 39 patients, and a monoclonal gammopathy in 9. There was no associated condition in 7 cases. Thirty patients received rituximab alone or in association with chemotherapy (n = 25). Among 51 patients with available follow-up, 34 patients were in clinical remission and 17 patients had active AE after a median follow-up of 3.9 years (interquartile range, 1.5-7.7). Three patients died. The presence of anti-C1-INH antibodies was associated with a lower probability of AE remission (hazard ratio, 0.29 [95% CI, 0.12-0.67]; P = .004). Relapse was less frequent in patients with lymphoma (risk ratio, 0.27 [95% CI, 0.09-0.80]; P = .019) and in patients treated with rituximab and chemotherapy (risk ratio, 0.31 [95% CI, 0.12-0.79]; P = .014). CONCLUSIONS: Rituximab is an efficient and well-tolerated therapeutic option in AE, especially in lymphoid malignancies and in the absence of detectable anti-C1-INH antibodies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Internal Medicine Department, Sorbonne Université, AP-HP, Hôpital Saint Antoine, Paris, France. Electronic address: galith.kalmi@aphp.fr.
- Internal Medicine Department, Nord-Université Paris Cité, AP-HP, Hôpital Beaujon, Clichy-sous-Bois, France.
- Dermatology Department, University Hospital, Clermont-Ferrand, France.
- Internal Medicine Department, Hospices Civils de Lyon, Lyon, France.
- Internal Medicine Department, Saint Grégoire Hospital, Rennes, France.
- Internal Medicine Department, Centre Hospitalier, Niort, France.
Zitieren
APA
Kalmi, G., Nguyen, Y., Amarger, S., Aubineau, M., Bibes, B., Blanchard-Delaunay, C., Boccon-Gibod, I., Bouillet, L., Coppo, P., Dalmas, M. C., Debord-Peguet, S., Defendi, F., Demoreuil, C., Du-Thanh, A., Gayet, S., Hadjadj, J., Jeandel, P. Y., Launay, D., Ly, K. H., …, & Gobert, D. (2024). Efficacy and Safety of Rituximab-Based Treatments in Angioedema With Acquired C1-Inhibitor Deficiency. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2023.10.017
Vancouver
Kalmi G, Nguyen Y, Amarger S, Aubineau M, Bibes B, Blanchard-Delaunay C, et al. Efficacy and Safety of Rituximab-Based Treatments in Angioedema With Acquired C1-Inhibitor Deficiency. The Journal of Allergy and Clinical Immunology: In Practice. 2024. doi:10.1016/j.jaip.2023.10.017
BibTeX
@article{Kalmi2024,
author = {Kalmi, Galith and Nguyen, Yann and Amarger, Stephanie and Aubineau, Magali and Bibes, Beatrice and Blanchard-Delaunay, Claire and Boccon-Gibod, Isabelle and Bouillet, Laurence and Coppo, Paul and Dalmas, Marie-Caroline and Debord-Peguet, Sophie and Defendi, Federica and Demoreuil, Claire and Du-Thanh, Aurélie and Gayet, Stephane and Hadjadj, Jerôme and Jeandel, Pierre-Yves and Launay, David and Ly, Kim Heang and Avoy, Chloé Mc and Niault, Mathilde and Ollivier, Yann and Pelletier, Fabien and Porneuf, Marc and Roos-Weil, Damien and Fain, Olivier and Gobert, Delphine},
title = {Efficacy and Safety of Rituximab-Based Treatments in Angioedema With Acquired C1-Inhibitor Deficiency},
journal = {The Journal of Allergy and Clinical Immunology: In Practice},
year = {2024},
doi = {10.1016/j.jaip.2023.10.017}
}
EUVIMED